MMS · Maximus, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.43B | $5.31B | $4.90B | $4.63B | $4.25B | $3.46B |
| Cost of Revenue | $4.10B | $4.05B | $3.88B | $3.69B | $3.31B | $2.75B |
| Gross Profit | $1.33B | $1.25B | $1.03B | $939.81M | $946.98M | $711.00M |
| R&D | - | - | - | - | - | - |
| SG&A | $713.11M | $671.58M | $639.22M | $534.49M | $494.09M | $387.09M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $41.67M | $33.96M | $54.73M | $42.33M | $46.36M | $64.53M |
| Operating Income | $528.29M | $488.50M | $294.79M | $325.90M | $408.53M | $288.28M |
| Interest Expense | $84.08M | $82.44M | - | - | - | $2.06M |
| Income Tax | $125.81M | $99.59M | $48.50M | $73.27M | $92.48M | $72.55M |
| Net Income | $319.03M | $306.91M | $161.79M | $203.83M | $291.20M | $214.51M |
| EPS - Basic | $5.56 | $5.03 | $2.65 | $3.30 | $4.69 | $3.40 |
| EPS - Diluted | $5.51 | $4.99 | $2.63 | $3.29 | $4.67 | $3.39 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $222.35M | $183.12M | $65.41M | $40.66M | $135.06M | $71.74M |
| Accounts Receivable | $898.10M | $879.51M | $826.87M | $807.11M | $834.82M | $622.87M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $1.25B | $1.20B | $1.06B | $1.03B | $1.08B | $932.56M |
| Total Assets | $4.07B | $4.13B | $3.99B | $3.99B | $4.12B | $2.02B |
| Current Liabilities | $765.16M | $807.53M | $723.01M | $774.45M | $789.43M | $561.17M |
| Long-term Debt | $1.28B | $1.09B | $1.16B | $1.29B | $1.43B | $18.02M |
| Total Liabilities | $2.40B | $2.29B | $2.32B | $2.44B | $2.64B | $782.88M |
| Stockholders' Equity | $1.67B | $1.84B | $1.67B | $1.55B | $1.48B | $1.24B |
| Retained Earnings | $1.06B | $1.28B | $1.12B | $1.03B | $987.83M | $770.50M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $429.37M | $515.26M | $314.34M | $289.84M | $517.32M | $244.59M |
| Investing Cash Flow | ($60.26M) | ($129.10M) | ($80.96M) | ($54.01M) | ($1.84B) | ($44.14M) |
| Financing Cash Flow | ($343.88M) | ($275.65M) | ($250.80M) | ($248.27M) | $1.39B | ($230.09M) |
| CapEx | $63.21M | $114.19M | $90.69M | $56.15M | $36.56M | $40.71M |
| Free Cash Flow | $366.16M | $401.07M | $223.65M | $233.69M | $480.76M | $203.88M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 24.6% | 23.6% | 21.0% | 20.3% | 22.3% | 20.5% |
| Operating margin | 9.7% | 9.2% | 6.0% | 7.0% | 9.6% | 8.3% |
| EBITDA margin | 10.5% | 9.8% | 7.1% | 8.0% | 10.7% | 10.2% |
| Net margin | 5.9% | 5.8% | 3.3% | 4.4% | 6.8% | 6.2% |
| Free cash flow margin | 6.7% | 7.6% | 4.6% | 5.0% | 11.3% | 5.9% |
| FCF / Net income | 1.15 | 1.31 | 1.38 | 1.15 | 1.65 | 0.95 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 13.1% | 12.7% | 13.0% | 11.5% | 11.6% | 11.2% |
| Effective tax rate | 28.3% | 24.5% | 23.1% | 26.4% | 24.1% | 25.3% |
| Return on assets | 7.8% | 7.4% | 4.1% | 5.1% | 7.1% | 10.6% |
| Return on equity | 19.1% | 16.7% | 9.7% | 13.2% | 19.7% | 17.3% |
| Return on invested capital | 12.8% | 12.6% | 8.0% | 8.4% | 10.7% | 17.1% |
| Liquidity | ||||||
| Current ratio | 1.64 | 1.49 | 1.46 | 1.33 | 1.37 | 1.66 |
| Quick ratio | 1.64 | 1.49 | 1.46 | 1.33 | 1.37 | 1.66 |
| Cash ratio | 0.29 | 0.23 | 0.09 | 0.05 | 0.17 | 0.13 |
| Leverage | ||||||
| Debt / Equity | 0.77 | 0.59 | 0.70 | 0.83 | 0.97 | 0.01 |
| Debt / Assets | 0.31 | 0.26 | 0.29 | 0.32 | 0.35 | 0.01 |
| Debt / EBITDA | 2.25 | 2.09 | 3.33 | 3.51 | 3.14 | 0.05 |
| Interest coverage | 6.3x | 5.9x | - | - | - | 140.0x |
| Equity multiplier | 2.43 | 2.24 | 2.39 | 2.58 | 2.78 | 1.63 |
| Liabilities / Assets | 0.59 | 0.55 | 0.58 | 0.61 | 0.64 | 0.39 |
| Efficiency | ||||||
| Asset turnover | 1.33 | 1.28 | 1.23 | 1.16 | 1.03 | 1.71 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 60d | 60d | 62d | 64d | 72d | 66d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 16.6x | 18.7x | 28.4x | 17.6x | 17.8x | 20.2x |
| P / B | 3.2x | 3.1x | 2.8x | 2.3x | 3.5x | 3.5x |
| P / S | 1.0x | 1.1x | 0.9x | 0.8x | 1.2x | 1.3x |
| EV / EBITDA | 11.1x | 12.7x | 16.3x | 13.1x | 14.3x | 12.1x |
| Growth | ||||||
| Revenue growth (YoY) | 2.4% | 8.2% | 5.9% | 8.9% | 22.9% | 41.2% |
| Revenue CAGR (3y) | 5.5% | 7.6% | 12.3% | 23.6% | 21.2% | 12.2% |
| Revenue CAGR (5y) | 9.4% | 16.7% | 15.4% | 13.6% | 12.1% | 10.5% |
| Gross profit growth (YoY) | 6.5% | 21.7% | 9.4% | -0.8% | 33.2% | 5.9% |
| Operating income growth (YoY) | 8.1% | 65.7% | -9.5% | -20.2% | 41.7% | -9.1% |
| Net income growth (YoY) | 3.9% | 89.7% | -20.6% | -30.0% | 35.8% | -10.9% |
| EPS growth (YoY) | 10.4% | 89.7% | -20.1% | -29.6% | 37.8% | -8.9% |
| EPS CAGR (3y) | 18.8% | 2.2% | -8.1% | -4.0% | 11.7% | 2.3% |
| EPS CAGR (5y) | 10.2% | 6.1% | -4.7% | 0.7% | 11.7% | 7.6% |
| FCF growth (YoY) | -8.7% | 79.3% | -4.3% | -51.4% | 135.8% | - |
| FCF CAGR (5y) | 12.4% | - | - | - | - | 13.7% |
| Book value growth (YoY) | -9.2% | 10.5% | 7.6% | 4.7% | 19.2% | -0.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-09-30.
Business segments
$5.43B totalU.S.Federal Services$3.07B · 56.5%
USServices$1.76B · 32.5%
Outside The United States$599.89M · 11.0%
Product / service
$5.43B totalProgram Operations$2.65B · 48.8%
Clinical Services$2.10B · 38.7%
Employment And Other$354.83M · 6.5%
Advanced Technology Solutions$324.73M · 6.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
2.34
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
8/9
Strong
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Business Services, NEC
Comparing MAXIMUS against the 5 most active filers in the same SIC group.
Dividends
$1.26/share trailing 12 months · +5.0% YoY
| Ex-date | Per share |
|---|---|
| May 15, 2026 | $0.3300 |
| Feb 13, 2026 | $0.3300 |
| Nov 14, 2025 | $0.3000 |
| Aug 15, 2025 | $0.3000 |
| May 15, 2025 | $0.3000 |
| Feb 14, 2025 | $0.3000 |
| Nov 15, 2024 | $0.3000 |
| Aug 15, 2024 | $0.3000 |
| May 14, 2024 | $0.3000 |
| Feb 14, 2024 | $0.3000 |
| Nov 14, 2023 | $0.3000 |
| Aug 14, 2023 | $0.2800 |
| May 12, 2023 | $0.2800 |
| Feb 14, 2023 | $0.2800 |
| Nov 14, 2022 | $0.2800 |
| Aug 12, 2022 | $0.2800 |
| May 12, 2022 | $0.2800 |
| Feb 14, 2022 | $0.2800 |
| Nov 12, 2021 | $0.2800 |
| Aug 12, 2021 | $0.2800 |
| May 13, 2021 | $0.2800 |
| Feb 11, 2021 | $0.2800 |
| Nov 12, 2020 | $0.2800 |
| Aug 13, 2020 | $0.2800 |